全球高磷血症治療市場：按產品類型、分銷渠道、地區 - 預測和分析 (2022-2028)

全球高磷血症治療市場規模預計將從 2021 年的 24.6 億美元達到 2028 年的 35.3 億美元，2022 年至 2028 年預測期內的複合年增長率預計為 5.3%。終末期腎病發病率的增加以及通過包括治療在內的多學科方法對其進行管理的需求不斷增長，正在推動市場增長。

本報告分析了全球高磷血症藥物市場，並提供了系統的信息，包括市場概況、市場規模、市場動態和公司概況。

目錄

執行摘要

市場概況

• 資料來源：執行摘要 - 市場概覽圖
• 資料來源：執行摘要 - 市場摘要數據表
• 資料來源：執行摘要——全球高磷血症市場特徵說明
• 資料來源：執行摘要 - 市場區域：按地區
• 資源：執行摘要——市場細分圖
• 資源：執行摘要 - 增量增長圖
• 資料來源：執行摘要 - 增量增長數據表
• 資源：執行摘要 - 供應商市場定位圖

母市場分析

市場概況

市場規模

• 市場動態
  • 資料來源：DROC 影響分析 (2021)
• 促進者
• 機會
• 抑製劑
• 任務
• SWOT分析

主要市場洞察

• 技術分析
  • （來源：數據表：技術名稱及詳情）
• 價格分析
  • （來源：數據表：技術名稱及價格明細）
• 供應鏈分析
  • （來源：詳細的供應鏈介紹）
• 價值鏈分析
  • （來源：詳細的價值鏈介紹）
• 市場生態系統
  • 資料來源：母市場生態系統市場分析
  • 圖：母市場的市場特徵
• 知識產權分析
  • （來源：數據表：產品/技術名稱、專利申請、發明人/公司名稱、收購公司）
• 貿易分析
  • （來源：數據表：進出口數據明細）
• 啟動分析
  • （來源：數據表：新興創業公司詳情）
• 原料分析
  • （來源：數據表：主要原材料圖譜）
• 創新矩陣
  • （來源：定位矩陣：映射新技術和現有技術）
• 管道產品分析
  • （來源：數據表：公司名稱和管道產品，按地區映射）
• 宏觀經濟指標

COVID-19 的影響

• 介紹
• 對經濟情景評估的影響
  • 資料來源：GDP數據-同比增長（%）（2016-2022）
• 修正後的市場規模
  • 資料來源：全球高磷血症藥物市場規模及預測數據表（百萬美元）（2022-2028）
• COVID 對關鍵細分市場的影響
  • 資料來源：細分市場規模和預測數據表（百萬美元）（2022-2028）
• COVID 策略：按公司分類
  • 資料來源：企業採用的主要戰略分析

市場動態和前景

• 市場動態
  • 資料來源：DROC 影響分析 (2021)
• 促進者
• 機會
• 抑製劑
• 任務
• 監管狀況
  • 資料來源：各地區法規數據表
• SWOT分析
• 波特分析
  • 競爭對手之間的競爭
• 圖：競爭對手之間的敵對關係，主要因素的影響（2021）
  • 替代品的威脅
• 圖表：替代產品威脅和關鍵因素的影響（2021 年）
  • 買方議價能力
• 圖表：影響買家議價能力的關鍵因素（2021 年）
  • 新進入者的威脅
• 圖表：新進入者威脅主要驅動因素的影響（2021 年）
  • 供應商的議價能力
• 圖表：供應商議價能力威脅的主要驅動因素的影響（2021 年）
• Skyquest對未來混亂的特殊洞察
  • 政治影響
  • 經濟影響
  • 社會影響
  • 技術影響
  • 對環境造成的影響
  • 法律影響
• 全球高磷血症藥物市場，按產品類型
• 市場細分
• 資料來源：市場份額圖表 (%) (2022-2028)
• 資料來源：市場份額數據表（%）（2022-2028）
• 司維拉姆
  • 市場估計和預測（2022-2028）
• 資料來源：市場份額圖表 (%) (2022-2028)
• 資料來源：市場規模和預測（百萬美元）（2022-2028）
• 鈣基磷盲劑
  • 市場估計和預測（2022-2028）
• 資料來源：市場份額圖表 (%) (2022-2028)
• 資料來源：市場規模和預測（百萬美元）（2022-2028）
• 鐵基磷結合劑
  • 市場估計和預測（2022-2028）
• 資料來源：市場份額圖表 (%) (2022-2028)
• 資料來源：市場規模和預測（百萬美元）（2022-2028）
• 碳酸鑭
  • 市場估計和預測（2022-2028）
• 資料來源：市場份額圖表 (%) (2022-2028)
• 資料來源：市場規模和預測（百萬美元）（2022-2028）
• 非磷酸鹽結合劑
  • 市場估計和預測（2022-2028）
• 資料來源：市場份額圖表 (%) (2022-2028)
• 資料來源：市場規模和預測（百萬美元）（2022-2028）
• 其他
  • 市場估計和預測（2022-2028）
• 資料來源：市場份額圖表 (%) (2022-2028)
• 資料來源：市場規模和預測（百萬美元）（2022-2028）
• 全球高磷血症藥物市場：按分銷渠道分類
• 市場細分
• 資料來源：市場份額圖表 (%) (2022-2028)
• 資料來源：市場份額數據表（%）（2022-2028）
• 醫院藥房
  • 市場估計和預測（2022-2028）
• 資料來源：市場份額圖表 (%) (2022-2028)
• 資料來源：市場規模和預測（百萬美元）（2022-2028）
• 零售藥店
  • 市場估計和預測（2022-2028）
• 資料來源：市場份額圖表 (%) (2022-2028)
• 資料來源：市場規模和預測（百萬美元）（2022-2028）
• 網上藥店
  • 市場估計和預測（2022-2028）
• 資料來源：市場份額圖表 (%) (2022-2028)
• 資料來源：市場規模和預測（百萬美元）（2022-2028）

市場規模：按地區

• 北美
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 歐洲其他地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 亞太其他地區
• 拉丁美洲
  • 巴西
  • 其他南美洲
• 中東和非洲
  • 海灣合作委員會國家
  • 南非
  • 其他中東和非洲

主要公司簡介

• 競爭格局
• 附件：受訪企業（2021年）
• 附件：企業定位矩陣（2021）
• 附：公司市場份額餅圖分析（%）（2021年）

Global Hyperphosphatemia Therapeutics Market was valued at USD 2.46 billion in 2021,and it is expected to reach USD 3.53 billion by 2028 at a CAGR of 5.3 % over the forecast period (2022-2028).

A condition called hyperphosphatemia is brought on by a high level of phosphate or phosphorous in the blood. The chemical phosphate, which contains the mineral phosphorous, is present in the body. The mineral phosphorus is crucial for the growth of teeth and bones as well as for converting food into body energy. The main locations of phosphate in the body are the teeth, bones, cells, and in very small quantities, the blood. The kidneys have a role in controlling the body's phosphate levels. However, a variety of issues or illnesses cause kidney damage, which results in a persistently high level of phosphate in the blood. People with end-stage kidney disease are more likely to develop hyperphosphatemia, which is very common in people with chronic kidney disease.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Hyperphosphatemia Therapeutics Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined by using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data. 

Segments covered in this report:

Global Hyperphosphatemia Therapeutics Market is segmented by Product Type, Distribution Channel, and Region. Based on Product Type, the market is segmented into Sevelamer, Calcium-based Phosphate Blinders, Iron-based Phosphate Binders, Lanthanum Carbonate, Non-phosphate Binders, and Others. Based on Distribution channels, the market is segmented into Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies. Based on region, the market is categorized into North America, Europe, Asia-Pacific, Latin America, and MEA.

Driver

An important driver that is enhancing the prospects for new pharmaceutical interventions in the market for treating hyperphosphatemia is the increasing incidence of end-stage renal disease. The available management options suggest using an integrated strategy to lower high levels of calcium and phosphorus. The patient population's high risk of cardiovascular events has increased the need for a multidisciplinary approach to managing it, including treatment. The market for treating hyperphosphatemia appears to have an unmet need for products combining calcium acetate and magnesium. The new class of phosphate binders is of particular interest. Clinical trials that specifically focus on evaluating them for their effectiveness, tolerability, and safety in advanced chronic kidney disease are therefore urgently needed (CKD).

Restraint

One of the main factors limiting the market's growth is poor treatment compliance among dialysis patients as a result of their heavy pill load. For instance, a dialysis patient is typically expected to take 10 to 12 different types of medications, according to a National Center for Biotechnology Information (NCBI) article. Nearly 80% of patients take four or more pills daily from phosphate binders, which can have negative side effects like gastrointestinal intolerance. Therefore, it is anticipated that these factors will limit the uptake of phosphate binders among CKD patients, thereby limiting the market's expansion.

Market Trends

It is very difficult to achieve ideal phosphate control in CKD patients receiving dialysis. The ability to control phosphate levels in dialysis patients has not significantly improved despite the extraordinary advancements in dialysis techniques over the years. Phosphate binders also have a number of negative side effects. Researchers are therefore concentrating on the introduction of new hyperphosphatemia therapeutics and updating the treatment guidelines in order to improve the treatment option for hyperphosphatemia. Phosphate binders are expected to be replaced by non-phosphate binders in the treatment of hyperphosphatemia, such as Tenapanor, an inhibitor of the hydrogen/sodium exchanger isoform 3 (NHE3), which is currently being researched. By 2021, the drug is expected to go on sale.

Table of Contents

Executive Summary

Market overview

• Exhibit: Executive Summary - Chart on Market Overview
• Exhibit: Executive Summary - Data Table on Market Overview
• Exhibit: Executive Summary - Chart on Global Global Hyperphosphatemia Therapeutics Market Characteristics
• Exhibit: Executive Summary - Chart on Market by Geography
• Exhibit: Executive Summary - Chart on Market Segmentation
• Exhibit: Executive Summary - Chart on Incremental Growth
• Exhibit: Executive Summary - Data Table on Incremental Growth
• Exhibit: Executive Summary - Chart on Vendor Market Positioning

Parent Market Analysis

Market overview

Market size

• Market Dynamics
  • Exhibit: Impact analysis of DROC, 2021
    • Drivers
    • Opportunities
    • Restraints
    • Challenges
• SWOT Analysis

KEY MARKET INSIGHTS

• Technology Analysis
  • (Exhibit: Data Table: Name of technology and details)
• Pricing Analysis
  • (Exhibit: Data Table: Name of technology and pricing details)
• Supply Chain Analysis
  • (Exhibit: Detailed Supply Chain Presentation)
• Value Chain Analysis
  • (Exhibit: Detailed Value Chain Presentation)
• Ecosystem Of the Market
  • Exhibit: Parent Market Ecosystem Market Analysis
  • Exhibit: Market Characteristics of Parent Market
• IP Analysis
  • (Exhibit: Data Table: Name of product/technology, patents filed, inventor/company name, acquiring firm)
• Trade Analysis
  • (Exhibit: Data Table: Import and Export data details)
• Startup Analysis
  • (Exhibit: Data Table: Emerging startups details)
• Raw Material Analysis
  • (Exhibit: Data Table: Mapping of key raw materials)
• Innovation Matrix
  • (Exhibit: Positioning Matrix: Mapping of new and existing technologies)
• Pipeline product Analysis
  • (Exhibit: Data Table: Name of companies and pipeline products, regional mapping)
• Macroeconomic Indicators

COVID IMPACT

• Introduction
• Impact On Economy-scenario Assessment
  • Exhibit: Data on GDP - Year-over-year growth 2016-2022 (%)
• Revised Market Size
  • Exhibit: Data Table on Global Global Hyperphosphatemia Therapeutics Market size and forecast 2021-2027 ($ million)
• Impact Of COVID On Key Segments
  • Exhibit: Data Table on Segment Market size and forecast 2021-2027 ($ million)
• COVID Strategies By Company
  • Exhibit: Analysis on key strategies adopted by companies

MARKET DYNAMICS & OUTLOOK

• Market Dynamics
  • Exhibit: Impact analysis of DROC, 2021
    • Drivers
    • Opportunities
    • Restraints
    • Challenges
• Regulatory Landscape
  • Exhibit: Data Table on regulation from different region
• SWOT Analysis
• Porters Analysis
  • Competitive rivalry
    • Exhibit: Competitive rivalry Impact of key factors, 2021
  • Threat of substitute products
    • Exhibit: Threat of Substitute Products Impact of key factors, 2021
  • Bargaining power of buyers
    • Exhibit: buyers bargaining power Impact of key factors, 2021
  • Threat of new entrants
    • Exhibit: Threat of new entrants Impact of key factors, 2021
  • Bargaining power of suppliers
    • Exhibit: Threat of suppliers bargaining power Impact of key factors, 2021
• Skyquest special insights on future disruptions
  • Political Impact
  • Economic impact
  • Social Impact
  • Technical Impact
  • Environmental Impact
  • Legal Impact

Global Global Hyperphosphatemia Therapeutics Market by Product Type

• Market segments
  • Exhibit: Chart on Market share 2021-2027 (%)
  • Exhibit: Data table on Market share 2021-2027 (%)
• Sevelamer
  • Market Estimates & Forecast, 2020-2027
    • Exhibit: Chart on Market share 2021-2027 (%)
    • Exhibit: Market size and forecast 2021-2027 ($ million)
• Calcium-based Phosphate Blinders
  • Market Estimates & Forecast, 2020-2027
    • Exhibit: Chart on Market share 2021-2027 (%)
    • Exhibit: Market size and forecast 2021-2027 ($ million)
• Iron-based Phosphate Binders
  • Market Estimates & Forecast, 2020-2027
    • Exhibit: Chart on Market share 2021-2027 (%)
    • Exhibit: Market size and forecast 2021-2027 ($ million)
• Lanthanum Carbonate
  • Market Estimates & Forecast, 2020-2027
    • Exhibit: Chart on Market share 2021-2027 (%)
    • Exhibit: Market size and forecast 2021-2027 ($ million)
• Non-phosphate Binders
  • Market Estimates & Forecast, 2020-2027
    • Exhibit: Chart on Market share 2021-2027 (%)
    • Exhibit: Market size and forecast 2021-2027 ($ million)
• Others
  • Market Estimates & Forecast, 2020-2027
    • Exhibit: Chart on Market share 2021-2027 (%)
    • Exhibit: Market size and forecast 2021-2027 ($ million)

Global Global Hyperphosphatemia Therapeutics Market by Distribution Channel

• Market segments
  • Exhibit: Chart on Market share 2021-2027 (%)
  • Exhibit: Data table on Market share 2021-2027 (%)
• Hospital Pharmacies
  • Market Estimates & Forecast, 2020-2027
    • Exhibit: Chart on Market share 2021-2027 (%)
    • Exhibit: Market size and forecast 2021-2027 ($ million)
• Retail Pharmacies
  • Market Estimates & Forecast, 2020-2027
    • Exhibit: Chart on Market share 2021-2027 (%)
    • Exhibit: Market size and forecast 2021-2027 ($ million)
• Online Pharmacies
  • Market Estimates & Forecast, 2020-2027
    • Exhibit: Chart on Market share 2021-2027 (%)
    • Exhibit: Market size and forecast 2021-2027 ($ million)

Market Size by Region

• Chart on Market share by geography 2021-2027 (%)
• Data Table on Market share by geography 2021-2027(%)
• North America
  • Chart on Market share by country 2021-2027 (%)
  • Data Table on Market share by country 2021-2027(%)
  • USA
    • Exhibit: Chart on Market share 2021-2027 (%)
    • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Canada
    • Exhibit: Chart on Market share 2021-2027 (%)
    • Exhibit: Market size and forecast 2021-2027 ($ million)
• Europe
  • Chart on Market share by country 2021-2027 (%)
  • Data Table on Market share by country 2021-2027(%)
  • Germany
    • Exhibit: Chart on Market share 2021-2027 (%)
    • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Spain
    • Exhibit: Chart on Market share 2021-2027 (%)
    • Exhibit: Market size and forecast 2021-2027 ($ million)
  • France
    • Exhibit: Chart on Market share 2021-2027 (%)
    • Exhibit: Market size and forecast 2021-2027 ($ million)
  • UK
    • Exhibit: Chart on Market share 2021-2027 (%)
    • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Rest of Europe
    • Exhibit: Chart on Market share 2021-2027 (%)
    • Exhibit: Market size and forecast 2021-2027 ($ million)
• Asia Pacific
  • Chart on Market share by country 2021-2027 (%)
  • Data Table on Market share by country 2021-2027(%)
  • China
    • Exhibit: Chart on Market share 2021-2027 (%)
    • Exhibit: Market size and forecast 2021-2027 ($ million)
  • India
    • Exhibit: Chart on Market share 2021-2027 (%)
    • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Japan
    • Exhibit: Chart on Market share 2021-2027 (%)
    • Exhibit: Market size and forecast 2021-2027 ($ million)
  • South Korea
    • Exhibit: Chart on Market share 2021-2027 (%)
    • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Rest of Asia Pacific
    • Exhibit: Chart on Market share 2021-2027 (%)
    • Exhibit: Market size and forecast 2021-2027 ($ million)
• Latin America
  • Chart on Market share by country 2021-2027 (%)
  • Data Table on Market share by country 2021-2027(%)
  • Brazil
    • Exhibit: Chart on Market share 2021-2027 (%)
    • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Rest of South America
    • Exhibit: Chart on Market share 2021-2027 (%)
    • Exhibit: Market size and forecast 2021-2027 ($ million)
• Middle East & Africa (MEA)
  • Chart on Market share by country 2021-2027 (%)
  • Data Table on Market share by country 2021-2027(%)
  • GCC Countries
    • Exhibit: Chart on Market share 2021-2027 (%)
    • Exhibit: Market size and forecast 2021-2027 ($ million)
  • South Africa
    • Exhibit: Chart on Market share 2021-2027 (%)
    • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Rest of MEA
    • Exhibit: Chart on Market share 2021-2027 (%)
    • Exhibit: Market size and forecast 2021-2027 ($ million)

KEY COMPANY PROFILES

• Competitive Landscape
  • Total number of companies covered
    • Exhibit: companies covered in the report, 2021
  • Top companies market positioning
    • Exhibit: company positioning matrix, 2021
  • Top companies market Share
    • Exhibit: Pie chart analysis on company market share, 2021(%)